Abstract
Purpose Fenfluramine and cannabidiol are licensed as add-on therapies for the treatment of seizures in Dravet syndrome (DS); however, there are no comparative trials of these therapies. We assessed the comparative effectiveness of fenfluramine (with/without concomitant stiripentol) versus cannabidiol (with/irrespective of concomitant clobazam, using robust indirect comparison methods.
Methods We systematically searched for randomised controlled trials (RCTs) of licensed regimens published up to 30 November 2021. Outcomes of interest were placebo-adjusted reductions from baseline in monthly convulsive seizure frequency (MCSF), the odds of achieving ≥25%, ≥50%, ≥75% and 100% reductions from baseline in MCSF, and the odds of experiencing serious treatment-emergent adverse events (TEAEs). Comparative efficacy and safety were assessed using Bayesian network meta-analysis (NMA). PROSPERO registration: CRD42021296141.
Results We identified five relevant placebo-controlled RCTs (three for fenfluramine; two for cannabidiol; N=667). All licensed regimens of fenfluramine and cannabidiol significantly reduced MCSF compared with standard of care. When indirectly comparing fenfluramine 0.7mg/kg/day (without concomitant stiripentol) and fenfluramine 0.4mg/kg/day (with concomitant stiripentol) versus cannabidiol 10mg/kg/day, irrespective of clobazam use, the mean differences in placebo-adjusted reduction from baseline in MCSF were 47.3% (95%CrI: 18.9, 64.7) and 35.1% (1.0, 57.5), respectively, and versus cannabidiol 10mg/kg/day plus clobazam were 37.2% (2.0, 59.7) and 23.5% (−20.2, 51.3), respectively. For these outcomes, and for the proportion of patients achieving ≥25%, ≥50% and ≥75% reductions in MCSF, Bayesian treatment ranking indicated ≥99% probability that fenfluramine is the most effective therapy versus <1% probability for cannabidiol 10 or 20mg/kg/day (maximum recommended dose), with/irrespective of concomitant clobazam. Fenfluramine regimens had lower odds of serious TEAEs.
Conclusion NMA using RCT data indicates fenfluramine provides superior convulsive seizure control compared to cannabidiol across all licensed dose regimens and is comparatively well-tolerated. Fenfluramine may meet the need for a highly effective and tolerable add-on therapy to control seizures in DS.
What is already known on this topic
What is already known on this topic
Fenfluramine (Fintepla®) is a recently licensed add-on therapy to standard of care antiepileptic drugs for the treatment of seizures in Dravet syndrome.
Cannabidiol (Epidiolex®/Epidyolex®) is also licensed for this use. In Europe cannabidiol is only licensed for use with concomitant clobazam.
There are no direct comparative data to inform on the relative efficacy and safety of these therapies in the management of seizures in Dravet syndrome. No indirect comparisons have been conducted across the full licensed dose regimens of these therapies.
What this study adds
What this study adds
Based on NMA using RCT data, fenfluramine provides superior convulsive seizure control in Dravet syndrome compared with cannabidiol across all licensed dose regimens, and is comparatively well tolerated.
Fenfluramine may meet the need for a highly effective and tolerable add-on therapy to control seizures in Dravet syndrome
Competing Interest Statement
This study was funded by Zogenix International Ltd, manufacturer of FINTEPLA (fenfluramine). WL and TT are employees and shareholders of Zogenix International Ltd. MS and NH have received consulting fees from Zogenix International Ltd for this and other projects.
Funding Statement
This study was funded by Zogenix International Ltd, the manufacturer of FINTEPLA (fenfluramine).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Zogenix International Ltd does not currently have a data sharing policy. All data used in the analyses are available in the cited references.
